

(19) **DANMARK**



Patent- og  
Varemærkestyrelsen

(10) **DK/EP 2144611 T3**

(12) Oversættelse af  
europæisk patentskrift

- 
- (51) Int.Cl.: **A 61 K 31/436 (2006.01)** **A 61 P 35/00 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2015-08-10**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2015-06-17**
- (86) Europæisk ansøgning nr.: **08742616.9**
- (86) Europæisk indleveringsdag: **2008-04-08**
- (87) Den europæiske ansøgnings publiceringsdag: **2010-01-20**
- (86) International ansøgning nr.: **US2008004501**
- (87) Internationalt publikationsnr.: **WO2008124125**
- (30) Prioritet: **2007-04-10 US 922759 P**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR**
- (73) Patenthaver: **Wyeth LLC, 235 East 42nd Street, New York, NY 10017-5755, USA**
- (72) Opfinder: **DUKART, Gary, 1714 Benjamin Drive, Ambler, PA 19002, USA**  
**GIBBONS, James, Joseph, Jr., 33 Terrace Drive, Westwood, NJ 07675, USA**  
**BERKENBLIT, Anna, 60 Hoover Road, Needham, MA 02494, USA**  
**FEINGOLD, Jay, Marshall, 230 Indian Creek Road, Wynnewood, PA 19096, USA**
- (74) Fuldmægtig i Danmark: **Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S, Danmark**
- (54) Benævnelse: **Antitumoraktivitet af temsirolimus ved papillært renalcellecarcinom**
- (56) Fremdragne publikationer:  
**WO-A-2004/093854**  
**WO-A-2004/097052**  
**DUTCHER J. P. ET AL.: "Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN)" JOURNAL OF CLINICAL ONCOLOGY & ASCO ANNUAL MEETING PROCEEDINGS, vol. 25, no. 18S, 20 June 2007 (2007-06-20), page 5033, XP002489424 ISSN: 0732-183X**  
**SCHRADER A J ET AL: "Metastatic non-clear cell renal cell carcinoma: current therapeutic options." BJU INTERNATIONAL, [Online] vol. 101, no. 11, June 2008 (2008-06), pages 1343-1345, XP002489425 ISSN: 1464-410X [retrieved on 2008-01-30]**  
**M. J. RATAIN: 'Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma' JOURNAL OF CLINICAL ONCOLOGY vol. 24, no. 16, 08 May 2006, pages 2505 - 2512, XP055025289 DOI: 10.1200/JCO.2005.03.6723 ISSN: 0732-183X**  
**"GENITOURINARY CANCERS", CANCER INVESTIGATION, MARCEL DEKKER INC, US, vol. 25, no. S1, 19 September 2007 (2007-09-19), pages 17-23, XP009158701, ISSN: 0735-7907, DOI: 10.1080/07357900701571783**  
**BURCZYNSKI MICHAEL E ET AL: "Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma", CLINICAL CANCER RESEARCH, THE**

Fortsættes ...

AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 11, no. 3, 1 February 2005 (2005-02-01), pages 1181-1189, XP002392224, ISSN: 1078-0432

ATKINS M B ET AL: "RANDOMIZED PHASE II STUDY OF MULTIPLE DOSE LEVELS OF CCI-779, A NOVEL MAMMALIAN TARGET OF RAPAMYCIN KINASE INHIBITOR, IN PATIENTS WITH ADVANCED REFRACTORY RENAL CELL CARCINOMA", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 22, no. 5, 1 March 2004 (2004-03-01), pages 909-918, XP008034968, ISSN: 0732-183X, DOI: 10.1200/JCO.2004.08.185

HUDES G ET AL: "A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)", INTERNET CITATION, 20 June 2006 (2006-06-20), pages 1-2, XP002674553, ISSN: 0732-183X Retrieved from the Internet: URL:[http://www.asco.org/asco2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=40&abstractID=30421](http://www.asco.org/asco2/Meetings/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=30421) [retrieved on 2012-04-24]

XIMING J YANG ET AL: 'A Molecular Classification of Papillary Renal Cell Carcinoma' CANCER RESEARCH, [Online] 01 July 2005, pages 5628 - 5637, XP055100585 Retrieved from the Internet: <URL:<http://cancerres.aacrjournals.org/content/65/13/5628.full.pdf>> [retrieved on 2014-02-06]

R. J. MOTZER: 'Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non-Clear-Cell Histology' JOURNAL OF CLINICAL ONCOLOGY vol. 20, no. 9, 01 May 2002, pages 2376 - 2381, XP055100162 DOI: 10.1200/JCO.2002.11.123 ISSN: 0732-183X

## DESCRIPTION

### BACKGROUND OF THE INVENTION

[0001] CCI-779 is rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid, an ester of rapamycin which has demonstrated significant inhibitory effects on tumor growth in both *in vitro* and *in vivo* models. This compound is now known generically under the name temsirolimus. The use of CCI-779 alone [see, e.g., US Patent 7,189,735] or in combination with other active agents [see, e.g., US Published Patent Application No. 2004-0258662 A1] has been described.

[0002] Renal cell carcinoma (RCC) is the most common primary renal malignant neoplasm in adults, accounting for more than 85% of all malignant kidney tumors and 2% of all adult malignancies. The majority of renal tumor malignancies arises from the tubular epithelium and is divided into several distinct subtypes based on morphologic features defined in the WHO International Histological Classification of Kidney Tumors.

[0003] The most common subtype, clear-cell renal cell carcinoma (cRCC) accounts for approximately 70-75% of all RCCs. Papillary renal cell carcinoma (pRCC) is the second most common subtype with ~15% of cases, followed by chromophobe (~5%), oncocytoma (~3%), and collecting duct (~2%).

[0004] PRCC is histologically characterized by the presence fibrovascular cores with tumor cells arranged in a papillary configuration. The majority of PRCC tumors show indolent behavior and have a limited risk of progression and mortality, but a distinct subset displays highly aggressive behavior [X. J. Yang et al, *Cancer Res.* 65, 5628 (2005)]. Treatment of PRCC has remained problematic. To date, no effective therapy is available for patients with advanced pRCC and patients with pRCC are usually excluded from clinical trials that are usually designed for the more common clear cell renal cell carcinoma.

[0005] Multi-kinase inhibitors, Sorafenib (Nexavair™) and Sunitinib (Sutent™), have gained FDA approval for treatment of patients with advanced renal cell carcinoma and metastatic kidney cancer. Both inhibitors are small molecule multi-receptor kinase inhibitors of VEGF, PDGFR, and others and have demonstrated improved progression-free survival with a decreased toxicity profiles compared to some of the conventional cytokine therapies. However, these clinical trials enrolled only patients with clear-cell pathology and excluded patients having non-clear cell pathology.

[0006] What are needed are effective methods for treating non-clear cell renal cell cancers.

### SUMMARY OF THE INVENTION

[0007] The present invention provides a method for treating non-clear cell renal cell cancers, for example papillary renal cell carcinoma, using an mTOR inhibitor CCI-779 (temsirolimus).

[0008] The present invention also provides an mTOR inhibitor CCI-779 (temsirolimus) for use in treating, or in the manufacture of a medicament for treating, non-clear cell cancers namely papillary renal cell carcinoma in a mammal.

[0009] In one aspect, the invention provides for the CCI-779 for use in treating hereditary type I papillary renal cell carcinoma. In yet a further aspect, the invention provides for the CCI-779 for use in treating hereditary type II papillary renal cell carcinoma. In still another aspect, the invention provides for the CCI-779 for use in treating sporadic papillary renal cell carcinoma.

[0010] Still other aspects and advantages of the invention will be apparent from the following detailed description of the invention.

### DETAILED DESCRIPTION OF THE INVENTION

[0011] This invention provides for the use of a rapamycin derivative, CCI-779, in treating, or preparing a medicament for treating, papillary renal cell carcinoma in a subject, for example for treating hereditary type I pRCC, hereditary type II pRCC, including sporadic pRCC, and including pRCC which is previously untreated, refractory, or advanced.

**[0012]** As used in accordance with this invention, the term "treating" means treating a mammal having papillary renal cell neoplasms by providing said mammal an effective amount of CCI-779 with the purpose of reducing or eradicating the neoplasms and/or prolonging survival of the mammal and/or palliation of the mammal.

**[0013]** As used herein, papillary renal cell carcinoma can be further classified into subtypes 1 and 2, and may be present as mixtures of these subtypes. Type 1 is characterized as consisting of papillae and tubular structures covered by small cells with pale cytoplasm, small oval nuclei with inconspicuous nucleoli, frequent glomeruloid papillae, papillary edema, foamy macrophages in papillary cores, and psammoma bodies. Type 2 is characterized as consisting of papillae covered by large cells with abundant eosinophilic cytoplasm and pseudostratification. PRCC can also occur in both sporadic (non-hereditary) and hereditary forms.

**[0014]** As used in accordance with this invention, the term "providing," with respect to providing CCI-779, means either directly administering CCI-779, or administering a prodrug, derivative, or analog which will form an effective amount of CCI-779 within the body.

**[0015]** As used in accordance with this invention, the term "previously untreated" refers to neoplasms in patients that have not been treated with standard, systemic, chemotherapy or other approved or experimental treatments appropriate for that given neoplasm.

**[0016]** As used in accordance with this invention, the term "refractory" refers to neoplasms in patients which typically had progressed following treatment with standard chemotherapy that was appropriate for that given neoplasm.

**[0017]** As used herein, the term a **CCI-779** means rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (temsirolimus), and encompasses prodrugs, derivatives, pharmaceutically acceptable salts, or analogs thereof. The terms "CCI-779" and "temsirolimus" are used interchangeably throughout this specification.

**[0018]** The preparation of temsirolimus is described in US Patent 5,362,718. A regiospecific synthesis of temsirolimus is described in US Patent 6,277,983. Still another regiospecific method for synthesis of temsirolimus is described in US Patent Application No. 10/903,062, filed July 30, 2004 [published as US Patent Publication No. 2005-0033046-A1 on February 10, 2005], and its counterpart, International Patent Publication No. WO 2005/016935 (published April 7, 2005).

**[0019]** In one embodiment, temsirolimus is provided in the treatment of hereditary type I papillary renal cell carcinoma. In another embodiment, temsirolimus is provided in the treatment of hereditary type II papillary renal cell carcinoma. In still another embodiment, temsirolimus is provided in the treatment of sporadic papillary renal cell carcinoma. In still another embodiment, the papillary renal cell carcinoma is previously untreated. In another embodiment, the papillary renal cell carcinoma is advanced.

**[0020]** In another aspect, the papillary renal cell carcinoma is associated with poor-risk features, *i.e.*, prognostic factors for shortened patient survival. In further embodiments, the poor-risk features include: elevated serum lactate dehydrogenase levels; reduced hemoglobin levels; elevated serum calcium; time from initial diagnosis to randomization less than one year; a Karnofsky performance score of 70 or below; and multiple organ sites of metastases.

**[0021]** In one embodiment, temsirolimus is administered as the sole active agent, *e.g.*, excluding chemotherapeutic agents, such as alkylating agents; hormonal agents (*i.e.*, estramustine, tamoxifen, toremifene, anastrozole, or letrozole); antibiotics (*i.e.*, plicamycin, bleomycin, mitoxantrone, idarubicin, dactinomycin, mitomycin, or daunorubicin); antimitotic agents (*i.e.*, vinblastine, vincristine, teniposide, or vinorelbine); topoisomerase inhibitors (*i.e.*, topotecan, irinotecan, etoposide, or doxorubicin); and other agents (*i.e.*, hydroxyurea, trastuzumab, altretamine, rituximab, paclitaxel, docetaxel, L-asparaginase, or gemtuzumab ozogamicin); biochemical modulating agents, imatib, EGFR inhibitors such as EKB or other multi-kinase inhibitors, *e.g.*, those that targets serine/threonine and receptor tyrosine kinases in both the tumor cell and tumor vasculature, or immunomodulators (*i.e.*, interferons, IL-2, or BCG). Examples of interferons include interferon  $\alpha$  (alpha interferon), interferon  $\beta$ , interferon  $\gamma$ , and mixtures thereof.

**[0022]** In another embodiment, CCI-779 is the sole anti-neoplastic agent. In still another embodiment, CCI-779 is provided with a further active agent, provided that the further active agent is not an interferon, for example alpha interferon.

**[0023]** As is typical with oncology treatments, dosage regimens are closely monitored by the treating physician, based on numerous factors including the severity of the disease, response to the disease, any treatment related toxicities, age, and health of the patient. It is projected that initial i.v. infusion dosages of the temsirolimus will be from about 1 to 250 mg, about 5 to about 175 mg, or about 5 to about 25 mg, when administered on a weekly dosage regimen. In one embodiment, the dosage is 1 to 250 mg per week. In a further embodiment, the dosage is 25 mg per week. Other dosage regimens and variations are foreseeable,

and will be determined through physician guidance. It is preferred that the temsirolimus is administered by i.v. infusion or orally, preferably in the form of tablets or capsules. In one embodiment, administration is weekly for from one to 24 months. However, other periods of treatment are appropriate and are within the skill in the art.

**[0024]** Dosage regimens are expected to vary according to the route of administration. It is projected that the oral dosage of the temsirolimus useful in the invention will be 10 mg/ week to 250 mg/week, about 20 mg/week to about 150 mg/week, about 25 mg/week to about 100 mg/week, or about 30 mg/week to about 75 mg/week. For rapamycin, the projected oral dosage will be between 0.1 mg/day to 25 mg/day. Precise dosages will be determined by the administering physician based on experience with the individual subject to be treated.

**[0025]** Oral formulations containing the temsirolimus useful in this invention may comprise any conventionally used oral forms, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions. Capsules may contain mixtures of the active compound(s) with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc. Useful tablet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, surface modifying agents (including surfactants), suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, microcrystalline cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starches and powdered sugar. Preferred surface modifying agents include nonionic and anionic surface modifying agents. Representative examples of surface modifying agents include, but are not limited to, poloxamer 188, benzalkonium chloride, calcium stearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, magnesium aluminum silicate, and triethanolamine. Oral formulations herein may utilize standard delay or time release formulations to alter the absorption of the active compound(s). The oral formulation may also consist of administering the active ingredient in water or a fruit juice, containing appropriate solubilizers or emulsifiers as needed. Preferred oral formulations for rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid are described in US Patent Publication No. 2004/0077677 A1, published April 22, 2004.

**[0026]** In some cases it may be desirable to administer a temsirolimus composition directly to the airways in the form of an aerosol.

**[0027]** A temsirolimus composition may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

**[0028]** The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils. Preferred injectable formulations for rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid are described in US Patent Publication No. 2004/0167152 A1, published August 26, 2004.

**[0029]** For the purposes of this disclosure, transdermal administrations are understood to include all administrations across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues. Such administrations may be carried out using the present compounds, or pharmaceutically acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal).


**[0030]** Transdermal administration may be accomplished through the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is non toxic to the skin, and allows delivery of the agent for systemic absorption into the blood stream via the skin. The carrier may take any number of forms such as creams and ointments, pastes, gels, and occlusive devices. The creams and ointments may be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may also be suitable. A variety of occlusive devices may be used to release the active ingredient into the blood stream such as a semi-permeable membrane covering a reservoir containing the active ingredient with or without a carrier, or a matrix containing

the active ingredient. Other occlusive devices are known in the literature.

[0031] Suppository formulations may be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin. Water soluble suppository bases, such as polyethylene glycols of various molecular weights, may also be used.

[0032] Another mTOR inhibitor may be substituted for the temsirolimus in a method or composition used in the method described herein. As used herein, the term **mTOR inhibitor** means a compound or ligand, or a pharmaceutically acceptable salt thereof, that inhibits cell replication by blocking the progression of the cell cycle from G1 to S. The term includes the neutral tricyclic compound rapamycin (sirolimus) and other rapamycin compounds, including, *e.g.*, rapamycin derivatives, rapamycin analogues, other macrolide compounds that inhibit mTOR activity, and all compounds included within the definition below of the term "a rapamycin". These include compounds with a structural similarity to "a rapamycin", *e.g.*, compounds with a similar macrocyclic structure that have been modified to enhance therapeutic benefit. FK-506 can also be used.

[0033] As used herein, the term **a rapamycin** defines a class of immunosuppressive compounds that contain the basic rapamycin nucleus as shown below.



The rapamycins include compounds that are chemically or biologically modified as derivatives of the rapamycin nucleus, while still retaining immunosuppressive properties. Accordingly, the term **a rapamycin** includes rapamycin, and esters, ethers, carbamates, oximes, hydrazones, and hydroxylamines of rapamycin, as well as rapamycins in which functional groups on the rapamycin nucleus have been modified, for example through reduction or oxidation. Also included in the term **a rapamycin** are pharmaceutically acceptable salts of rapamycins.

[0034] The term **a rapamycin** also includes 42- and/or 31-esters and ethers of rapamycin as described in the following patents: alkyl esters (U.S. Patent No. 4,316,885); aminoalkyl esters (U.S. Patent No. 4,650,803); fluorinated esters (U.S. Patent No. 5,100,883); amide esters (U.S. Patent No. 5,118,677); carbamate esters (U.S. Patent No. 5,118,678); silyl esters (U.S. Patent No. 5,120,842); aminodiester (U.S. Patent No. 5,162,333); sulfonate and sulfate esters (U.S. Patent No. 5,177,203); esters (U.S. Patent No. 5,221,670); alkoxyesters (U.S. Patent No. 5,233,036); O-aryl, -alkyl, -alkenyl, and -alkynyl ethers (U.S. Patent No. 5,258,389); carbonate esters (U.S. Patent No. 5,260,300); arylcarbonyl and alkoxy carbonyl carbamates (U.S. Patent No. 5,262,423); carbamates (U.S. Patent No. 5,302,584); hydroxyesters (U.S. Patent No. 5,362,718); hindered esters (U.S. Patent No. 5,385,908); heterocyclic esters (U.S. Patent No. 5,385,909); gem-disubstituted esters (U.S. Patent No. 5,385,910); amino alkanolic esters (U.S. Patent No. 5,389,639); phosphorylcarbamate esters (U.S. Patent No. 5,391,730); carbamate esters (U.S. Patent No. 5,411,967); carbamate esters (U.S. Patent No. 5,434,260); amidino carbamate esters (U.S. Patent No. 5,463,048); carbamate esters (U.S. Patent No. 5,480,988); carbamate esters (U.S. Patent No. 5,480,989); carbamate esters (U.S. Patent No. 5,489,680); hindered N-oxide esters (U.S. Patent No. 5,491,231); biotin esters (U.S. Patent No. 5,504,091); O-alkyl ethers (U.S. Patent No. 5,665,772); and PEG esters of rapamycin (U.S. Patent No. 5,780,462). The preparation of these esters and ethers is disclosed in the patents listed above.

[0035] Further included within the definition of the term **a rapamycin** are 27-esters and ethers of rapamycin, which are disclosed in U.S. Patent No. 5,256,790. Also described are C-27 ketone rapamycins which are reduced to the corresponding alcohol, which is in turn converted to the corresponding ester or ether. The preparation of these esters and ethers is disclosed in the patent listed above. Also included are oximes, hydrazones, and hydroxylamines of rapamycin are disclosed in U.S. Patent Nos. 5,373,014, 5,378,836, 5,023,264, and 5,563,145. The preparation of these oximes, hydrazones, and hydroxylamines is disclosed in the above-listed patents. The preparation of 42-oxorapamycin is disclosed in 5,023,263.

[0036] Examples of a rapamycin include, *e.g.*, rapamycin, 32-deoxorapamycin, 16-pent-2-ynioxy-32-deoxorapamycin, 16-pent-2-ynioxy-32(S)-dihydro-rapamycin, 16-pent-2-ynioxy-32(S)-dihydro-40-O-(2-hydroxyethyl)-rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779), 40-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin, or a pharmaceutically acceptable salt thereof, as disclosed in U.S. Patent No. 5,362,718, ABT578, or 40-(tetrazolyl)-rapamycin, 40-epi-(tetrazolyl)-rapamycin, *e.g.*, as disclosed in International Patent Publication No. WO 99/15530, or rapamycin analogs as disclosed in International Patent Publication No. WO 98/02441 and WO

01/14387, e.g., AP23573. In another embodiment, the compound is Certican™ (everolimus, 2-0-(2-hydroxy)ethyl rapamycin, Novartis, U.S. Patent No. 5,665,772).

[0037] The following standard pharmacological test procedure can be used to determine whether a compound is an mTOR inhibitor, as defined herein. Treatment of growth factor stimulated cells with an mTOR inhibitor like rapamycin completely blocks phosphorylation of serine 389 as evidenced by Western blot and as such constitutes a good assay for mTOR inhibition. Thus, whole cell lysates from cells stimulated by a growth factor (e.g. IGF1) in culture in the presence of an mTOR inhibitor should fail to show a band on an acrylamide gel capable of being labeled with an antibody specific for serine 389 of p70s6K.

[0038] In one embodiment, an effective amount of CCI-779 for use in treating papillary renal cell carcinoma in a mammal in need thereof in the absence of interferon alpha ( $\alpha$ -interferon or  $\alpha$ -IFN is provided. Also provided is the use of CCI-779 in the manufacture of a medicament for treatment regimen for papillary renal cell carcinoma in a mammal in need thereof, wherein CCI-779 is the sole active agent in the regimen. In still another embodiment, provided is the use of CCI-779 in the manufacture of a medicament for treatment regimen for papillary renal cell carcinoma in a mammal in need thereof, wherein CCI-779 is in a combination regimen, wherein said regimen excludes alpha interferon.

[0039] In a further aspect, it is herein described a product or pharmaceutical pack containing a course of an anti-neoplastic treatment for one individual mammal comprising one or more container(s) having one, one to four, or more unit(s) of temsirolimus in unit dosage form. In another aspect, pharmaceutical packs contain a course of anti-neoplastic treatment for one individual mammal comprising a container having a unit of a temsirolimus in unit dosage form.

[0040] The compositions are in packs or kits in a form ready for administration. In other aspect, the compositions of the invention are in concentrated form in packs, optionally with the diluent required to make a final solution for administration. In still other aspect, the product contains a compound useful in the invention in solid form and, optionally, a separate container with a suitable solvent or carrier for the compound useful in the invention.

[0041] In still other aspect, the above packs/kits include other components, e.g., instructions for dilution, mixing and/or administration of the product, other containers, syringes, needles, etc. Other such pack/kit components will be readily apparent to one of skill in the art.

[0042] The following examples are illustrative of the present invention.

#### **Example - CCI-779 as a Sole Systemic Active Agent against Non-Clear Cell Renal Cell Carcinoma**

[0043] In this phase III study, 626 advanced metastatic renal cell carcinoma patients from 26 countries were randomized to  $\alpha$ IFN or CCI-779 (temsirolimus) as first-line therapy. This group is a very poor prognosis group of patients with many risk factors for early death. Patients received 3 million units (MU) of  $\alpha$ IFN-alone subcutaneously 3 times/week, escalating to 18 MU or 25-mg CCI-779 intravenous infusion weekly.

[0044] Eligibility for this study required histologically confirmed, advanced (stage IV or recurrent disease) RCC with no prior systemic therapy for the disease. Subjects with central nervous system metastases, prior anticancer therapy for RCC and prior investigational therapy/agents within 4 weeks of randomization were excluded from the study.

[0045] The primary objective of this study was efficacy with a primary endpoint of overall survival. Secondary objectives of this study were safety, health outcomes, and additional efficacy endpoints. The secondary efficacy endpoints of this study were an evaluation of progression-free survival, response rate (complete and partial responses), clinical benefit rate, the duration of overall response, time to treatment failure, and health outcomes measurements. In addition, subject responses across all 3 treatment arms were evaluated based on screening tumor expression of proteins involved in the AKT-mTOR pathway. Other planned and post-hoc analyses were performed to assess influence of tumor histology (clear cell vs. non-clear cell), age (65 years old vs.  $\geq$  65 years old), and prognostic-risk groups (intermediate vs. poor).

[0046] The following summarizes the results (Table 1) that were obtained:  
Table 1 Overall Survival and Progression Free Survival in Phase III Study

Tumor Histology	Clear-Cell		Other	
	αIFN	TEMSR	αIFN	TEMSR
Patients, n (%)	170 (82)	169 (82)	36(18)	37(18)
OS median, mo (95%CI)	8.2 (6.6,10.4)	10.7 (8.5,13.0)	4.3 (3.2,7.3)	11.6 (8.9,14.5)
OS HR, TEMSR:IFN (95%CI)		0.82 (0.64,1.06)		0.49 (0.29,0.85)
PFS median, mo (95% CI)	3.7 (2.5,4.6)	5.5 (3.8,7.1)	1.8 (1.6,2.1)	7.0 (3.9,8.9)
PFS HR, TEMSR:IFN (95% CI)		0.76 (0.60,0.97)		0.38 (0.23,0.62)

[0047] The proportion of patients with different histologies was balanced across all arms of the study (81% clear-cell; 13% indeterminate; 6% non-clear cell). Of those with additional subtype data, 75% were papillary RCC. For patients with clear-cell tumors, median overall survival (OS) and progression-free survival (PFS) were longer for CCI-779 (TEMSR) vs. αIFN with hazard ratios (HR) of 0.82 and 0.76, respectively. For patients with other tumor histologies, median OS and PFS also were longer for TEMSR vs. αIFN with HR of 0.49 and 0.38, respectively. Among patients <65 years old, median OS and PFS were longer for TEMSR than for αIFN with HR of 0.62 and 0.61, respectively. There was no difference in OS or PFS for patients ≥ 65 years old treated with TEMSR or αIFN, but TEMSR had a better side effect profile than αIFN.

[0048] TEMSR prolonged PFS by 31% in patients with previously untreated clear-cell type, advanced renal cell carcinoma (advRCC)-with HR of 0.76 indicating that the risk of death or disease progression was reduced by 24%. TEMSR also improved OS by 22% in patients with previously untreated clear-cell advRCC vs. αIFN. A hazard ratio of 0.82 indicates an 18% reduction in risk of death for patients who received TEMSR as compared to αIFN.

[0049] TEMSR alone prolonged PFS by 163% in patients with previously untreated non clear-cell advRCC with a HR of 0.38 indicating that the risk of death or disease progression was reduced by 62%. TEMSR alone also improved OS by 104% in patients with previously untreated non clear-cell, advRCC vs.αIFN. A hazard ratio of 0.49 indicates a 51% reduction in risk of death for patients who received TEMSR as compared to αIFN.

[0050] In the population of patients <65yo, TEMSR prolonged PFS by 61% in patients with previously untreated advRCC. A hazard ratio of 0.62 indicates that the risk of death or disease progression was reduced by 38%. In the population of patients <65yo, TEMSR improved OS by 64% in patients with previously untreated advRCC vs. αIFN. A hazard ratio of 0.61 indicates a 39% reduction in risk of death for patients who received TEMSR as compared to αIFN.

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

### Patent documents cited in the description

- [US7189735B \[0001\]](#)
- [US20040258662A1 \[0001\]](#)
- [US5362718A \[0018\] \[0034\] \[0036\]](#)
- [US6277983B \[0018\]](#)
- [US10903062B \[0018\]](#)
- [US20050033046A1 \[0018\]](#)
- [WO2005016935A \[0018\]](#)
- [US20040077677A1 \[0025\]](#)
- [US20040167152A1 \[0028\]](#)
- [US4316885A \[0034\]](#)
- [US4650803A \[0034\]](#)
- [US5100883A \[0034\]](#)



- [US5118677A \[0034\]](#)
- [US5118678A \[0034\]](#)
- [US5120842A \[0034\]](#)
- [US5162333A \[0034\]](#)
- [US5177203A \[0034\]](#)
- [US5221670A \[0034\]](#)
- [US5233036A \[0034\]](#)
- [US5258389A \[0034\]](#)
- [US5260300A \[0034\]](#)
- [US5262423A \[0034\]](#)
- [US5302584A \[0034\]](#)
- [US5385908A \[0034\]](#)
- [US5385909A \[0034\]](#)
- [US5386910A \[0034\]](#)
- [US5389639A \[0034\]](#)
- [US5391730A \[0034\]](#)
- [US5411967A \[0034\]](#)
- [US5434260A \[0034\]](#)
- [US5463048A \[0034\]](#)
- [US5480989A \[0034\]](#)
- [US5480989A \[0034\]](#)
- [US5489680A \[0034\]](#)
- [US5491231A \[0034\]](#)
- [US5504091A \[0034\]](#)
- [US5665772A \[0034\] \[0036\]](#)
- [US5780462A \[0034\]](#)
- [US5256790A \[0035\]](#)
- [US5373014A \[0035\]](#)
- [US5378836A \[0035\]](#)
- [US5023264A \[0035\]](#)
- [US5563145A \[0035\]](#)
- [WO9915530A \[0036\]](#)
- [WO9802441A \[0036\]](#)
- [WO0114387A \[0036\]](#)
- [AP23573 \[0036\]](#)

**P a t e n t k r a v**

- 5 1. Rapamycin 42-ester med 3-hydroxy-2-(hydroxymethyl)-2-methylpropion-  
syre (CCI-779) til anvendelse ved behandling af fremskredent papillært re-  
nalcellecarcinom hos et pattedyr.
- 10 2. CCI-779 til anvendelse ifølge krav 1, hvor det fremskredne papillære re-  
nalcellecarcinom er udvalgt blandt arveligt type I papillært renalcellecarci-  
nom, arveligt type II papillært renalcellecarcinom og sporadisk papillært re-  
nalcellecarcinom.
- 15 3. CCI-779 til anvendelse ifølge krav 1 eller 2, hvor det fremskredne papillære  
renalcellecarcinom er tidligere ubehandlet fremskredent papillært renalcel-  
lecarcinom.
- 20 4. CCI-779 til anvendelse ifølge et af kravene 1 til 3, hvor det fremskredne  
papillære renalcellecarcinom er associeret med lavrisiko-træk.
5. CCI-779 til anvendelse ifølge et af kravene 1 til 4, hvor CCI-779 indgives  
intravenøst.
- 25 6. CCI-779 til anvendelse ifølge et af kravene 1 til 5, hvor CCI-779 indgives  
ugentligt i en til 24 måneder.
7. CCI-779 til anvendelse ifølge et af kravene 1 til 6, hvor CCI-779 indgives  
intravenøst med en dosis på 1 til 250 mg pr. uge.
- 30 8. CCI-779 til anvendelse ifølge krav 7, hvor CCI-779 indgives intravenøst  
med en dosis på 25 mg pr. uge.
9. CCI-779 til anvendelse ifølge et af kravene 1 til 8, hvor CCI-779 er det  
eneste anti-neoplastiske middel i regimet.
- 35 10. CCI-779 til anvendelse ifølge et af kravene 1 til 9, hvor CCI-779 er det  
eneste aktive middel i regimet.

11. CCI-779 til anvendelse ifølge et af kravene 1 til 9, yderligere omfattende et yderligere aktivt middel, forudsat at det yderligere aktive middel ikke er et interferon.

5        12. CCI-779 til anvendelse ifølge et af kravene 1 til 11 ved fravær af interferon alpha.

10       13. Anvendelse af rapamycin 42-ester med 3-hydroxy-2-(hydroxymethyl)-2-methylpropionsyre (CCI-779) til fremstilling af et medikament til behandling af fremskredent papillært renalcellecarcinom hos et pattedyr.